Home › NDC Lookup › Ingredients › Cephalexin › 68180-0441-02
cephalexin 250 mg/5mL For Suspension, 200 mL — NDC 68180-0441-02 package photo

cephalexin 250 mg/5mL For Suspension, 200 mL

by Lupin Pharmaceuticals, Inc. · 200 mL in 1 BOTTLE (68180-441-02)
NDC 68180-0441-02
🏷️ FDA NDC (as labeled) 68180-441-02 billing pads the product segment with a zero
This package
Contains200 mL Cost per mL$0.0508 NADAC Per package$10.16 / 200 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.0914/unit · Part D plans $0.1952/unit — full pricing hub ↓
Also comes in: 100 ml 68180-0441-01
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Cephalexin (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · May 23, 2025 — Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct. (Ascend Laboratories, LLC) · FDA recall D-0469-2025
Class II · May 23, 2025 — Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct. (Ascend Laboratories, LLC) · FDA recall D-0468-2025
Class III · May 10, 2024 — Labeling: Not Elsewhere Classified: Back label states Each contains: cephalexin monohydrate, USP equivalent to 2.5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g (Bryant Ranch Prepack, Inc.) · FDA recall D-0537-2024
Class III · May 10, 2024 — Labeling: Not Elsewhere Classified: Back Label states Each contains: cephalexin monohydrate, USP equivalent to 5g' on the back label instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g' (Bryant Ranch Prepack, Inc.) · FDA recall D-0539-2024
Class III · May 10, 2024 — Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g' (Bryant Ranch Prepack, Inc.) · FDA recall D-0538-2024
Class III · May 10, 2024 — Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g' (Bryant Ranch Prepack, Inc.) · FDA recall D-0540-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 68180-441-02
Product NDC 68180-441
11-digit billing NDC 68180044102
NCPDP billing unit ML — per mL (volume)
RxCUI 309110, 309113
UNII OBN7UDS42Y
Application # ANDA065234
SPL Set ID 25ef498a-7a7e-4543-a544-b9d0e99f9cd9
Established class (EPC) Cephalosporin Antibacterial
Chemical class Cephalosporins
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-09-06
Route ORAL
Dosage form FOR SUSPENSION
Substance CEPHALEXIN
GPI-14 02100020001915
GPI class Cephalexin
GCN Seq No 009046
GCN 39812
HICL code 013908
Ingredient (HICL) Cephalexin
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W1
Therapeutic class — intermediate (HIC2) Antibiotics
HIC3 code W1W
Therapeutic class — specific (HIC3) Cephalosporin Antibiotics - 1St Generation
AHFS code 08:12.06.04
AHFS class 1St Generation Cephalosporin Antibiotics
FDB label name CEPHALEXIN 250 MG/5 ML SUSP
FDB brand name Cephalexin
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 68180-441-02 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 68180-0441-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Cephalosporin Antibacterial class.

Pharmacologic class Cephalosporin Antibacterial
Drug family (ATC) First-generation cephalosporins
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerLupin Pharmaceuticals, Inc.
Application holderLUPIN LTD
FDA applicationANDA065234 (ANDA)
Labeler code68180
First marketedSep 2017
Product typeHuman Prescription Drug
Portfolio404 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CEPHALEXIN 250 MG/5 ML SUSP Ingredient Cephalexin
📗 Our plain-language guide HelloPharmacist
  • Cephalexin is an antibiotic used to treat bacterial infections — things like strep throat and other respiratory infections, ear infections, skin infections, bone infections, and ur...
  • Yes, you can take cephalexin with or without food — it's stable in stomach acid either way. If it upsets your stomach, taking it with a small meal or snack can help. Just try to ta...
  • The most common side effects are stomach-related — diarrhea, nausea, vomiting, or indigestion. These are usually mild and manageable. The ones to call your doctor about are: a seve...
  • What side effects should I watch out for?
📖 Read our full Cephalexin guide →
7
Nutrient depletion considerations

Cephalexin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Cephalexin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color Pink
FlavorStrawberry
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII WZB9127XOA
    A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII OJ245FE5EU
    Sodium benzoate is a salt derived from benzoic acid, a preservative. It's added to medicines to prevent growth of bacteria, fungi, and other microorganisms that could spoil the product.
  • UNII 4J2TY8Y81V
    A natural flavoring derived from strawberries that gives the medicine its strawberry taste and smell. It helps make the medicine more pleasant to take, especially for children.
  • UNII C151H8M554
    A natural sugar derived from sugar cane or sugar beets. It's used as a sweetener, filler, and binder to improve taste, add bulk, and help hold tablet or capsule ingredients together.
  • UNII TTV12P4NEE
    Xanthan gum is a thickening and stabilizing ingredient made from fermented corn or other sugars. It's added to medicines to improve texture, prevent separation of liquids and solids, and help the product stay consistent.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.051 $10.16 / 200 ml
Medicaid paysCMS SDUD · 12 mo $0.0914 $18.28 / 200 ml
Medicare drug plans payPart D · Q2 2026 $0.1952 $39.04 / 200 ml
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.099 $0.051
▼ Down 31% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Cephalexin 250 mg/5mL 67877-0545-68 Ascend 200 ml $0.051 AB Availability likely —
cephalexin 250 mg/5mLthis 68180-0441-02 Lupin 200 ml $0.051 AB Availability likely —
Cephalexin 250 mg/5mL 00093-4177-73 Teva 100 ml $0.075 AB Discontinued +48%
Cephalexin 250 mg/5mL 59651-0323-01 Aurobindo 100 ml $0.075 AB Availability likely +48%
Cephalexin 250 mg/5mL 62135-0481-42 Chartwell 100 ml $0.075 AB Availability likely +48%
Cephalexin 250 mg/5mL 50090-4795-00 A-S 200 ml — AB FDA listed —
Cephalexin 250 mg/5mL 50090-5196-00 A-S 100 ml — AB FDA listed —
cephalexin 250 mg/5mL 50090-6445-00 A-S 100 ml — AB FDA listed —
cephalexin 250 mg/5mL 50090-7091-00 A-S 200 ml — AB FDA listed —
Cephalexin 250 mg/5mL 63187-0205-00 Proficient 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 63629-8857-01 Bryant 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 63629-8858-01 Bryant 200 ml — AB FDA listed —
Cephalexin 250 mg/5mL 63629-9206-01 Bryant 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 63629-9207-01 Bryant 200 ml — AB FDA listed —
Cephalexin 250 mg/5mL 66267-0982-00 NuCare 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 68071-2889-02 NuCare 200 ml — AB FDA listed —
cephalexin 250 mg/5mL 68071-3587-02 NuCare 200 ml — AB FDA listed —
Cephalexin 250 mg/5mL 68071-5038-00 NuCare 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 68788-7529-01 Preferred 100 ml — AB FDA listed —
cephalexin 250 mg/5mL 68788-8686-02 Preferred 200 ml — AB FDA listed —
Cephalexin 250 mg/5mL 70518-4511-00 REMEDYREPACK 100 ml — AB FDA listed —
cephalexin 250 mg/5mL 71205-0553-00 Proficient 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 71335-2734-01 Bryant 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 71335-2877-01 Bryant 200 ml — AB FDA listed —
Cephalexin 250 mg/5mL 71335-2986-01 Bryant 100 ml — AB FDA listed —
Cephalexin 250 mg/5mL 72162-1851-01 Bryant 100 ml — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2017
On the market since
Sep 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 68180-0441-02, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
233.2K
Units reimbursed last 4 qtrs
49.7M
Gross reimbursed last 4 qtrs
$4.54M
Avg / prescription
$19.47
Avg / unit
$0.0914
Latest quarter Q4 2025
48.8KRx
Medicaid pays / mL
$0.0914
gross reimbursed
vs
NADAC / mL
$0.0508
acquisition cost
=
Spread
+$0.0406
+80% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
31% FFS 69% MCO
Fee-for-service · 72,174 Rx Managed care · 161,065 Rx
State Medicaid map
Alaska: 124,100 units · 16,930 per 100k residents AK Maine: 99,000 units · 7,097 per 100k residents ME Washington: 1,001,274 units · 12,817 per 100k residents WA Idaho: 151,140 units · 7,696 per 100k residents ID Montana: 87,552 units · 7,734 per 100k residents MT North Dakota: 68,800 units · 8,787 per 100k residents ND Minnesota: 461,904 units · 8,051 per 100k residents MN Wisconsin: 688,350 units · 11,647 per 100k residents WI Michigan: 1,341,606 units · 13,367 per 100k residents MI New York: 3,028,199 units · 15,473 per 100k residents NY Vermont: 57,900 units · 8,949 per 100k residents VT New Hampshire: 160,419 units · 11,442 per 100k residents NH Oregon: 435,950 units · 10,299 per 100k residents OR Nevada: 160,300 units · 5,019 per 100k residents NV Wyoming: 36,600 units · 6,267 per 100k residents WY South Dakota: 99,701 units · 10,849 per 100k residents SD Iowa: 593,505 units · 18,507 per 100k residents IA Illinois: 1,784,550 units · 14,221 per 100k residents IL Indiana: 1,713,800 units · 24,975 per 100k residents IN Ohio: 1,588,050 units · 13,475 per 100k residents OH Pennsylvania: 2,286,660 units · 17,643 per 100k residents PA New Jersey: 1,928,190 units · 20,756 per 100k residents NJ Massachusetts: 1,526,100 units · 21,798 per 100k residents MA California: 3,159,029 units · 8,107 per 100k residents CA Utah: 161,989 units · 4,741 per 100k residents UT Colorado: 356,333 units · 6,062 per 100k residents CO Nebraska: 329,600 units · 16,663 per 100k residents NE Missouri: 1,713,600 units · 27,657 per 100k residents MO Kentucky: 1,074,026 units · 23,730 per 100k residents KY West Virginia: 340,600 units · 19,243 per 100k residents WV Virginia: 1,534,950 units · 17,611 per 100k residents VA Maryland: 1,020,200 units · 16,508 per 100k residents MD Connecticut: 667,631 units · 18,458 per 100k residents CT Rhode Island: 278,900 units · 25,470 per 100k residents RI Arizona: 503,100 units · 6,770 per 100k residents AZ New Mexico: 412,496 units · 19,513 per 100k residents NM Kansas: 362,500 units · 12,330 per 100k residents KS Arkansas: 862,200 units · 28,112 per 100k residents AR Tennessee: 1,089,634 units · 15,291 per 100k residents TN North Carolina: 1,965,730 units · 18,142 per 100k residents NC South Carolina: 1,491,500 units · 27,759 per 100k residents SC Delaware: 65,200 units · 6,324 per 100k residents DE Oklahoma: 1,488,328 units · 36,722 per 100k residents OK Louisiana: 824,503 units · 18,026 per 100k residents LA Mississippi: 543,531 units · 18,487 per 100k residents MS Alabama: 1,090,740 units · 21,354 per 100k residents AL Georgia: 3,072,430 units · 27,858 per 100k residents GA D.C.: 56,075 units · 8,258 per 100k residents DC Hawaii: 44,734 units · 3,117 per 100k residents HI Texas: 4,377,094 units · 14,350 per 100k residents TX Florida: 1,205,890 units · 5,333 per 100k residents FL
Units reimbursed · per 100k residents
3,11736,722
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Oklahoma 36,722 /100k
2 Arkansas 28,112 /100k
3 Georgia 27,858 /100k
4 South Carolina 27,759 /100k
5 Missouri 27,657 /100k
6 Rhode Island 25,470 /100k
7 Indiana 24,975 /100k
8 Kentucky 23,730 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 ml68180-0441-01 243,319 Rx · $4,128,843
2 ml this page68180-0441-02 233,239 Rx · $4,540,474
Drug total (last 4 qtrs): 476,558 Rx · 90,032,301 units · $8,669,317 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Cephalexin — the program that covers self-administered drugs. 10 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Cephalexin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.31M
Claims incl. refills
1.8M
Beneficiaries
1.6M
Spend / beneficiary
$8.47
Spend / claim
$7.30
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Cephalexin — the ingredient across all brands.

Top reported reactions

Chronic Kidney Disease2,157
Renal Failure1,558
Acute Kidney Injury1,550
Diarrhoea1,405
Pain1,397
Fatigue1,303
Nausea1,297

Reporter sex

0 reports

Serious outcomes

Hospitalization7,494
Death1,794
Disabling724
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 2,043 805
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
68180-0441-01 100 mL in 1 BOTTLE (68180-441-01) $0.0750 / mL $7.50 2017-09-29 Active
68180-0441-02 You're viewing this 200 mL in 1 BOTTLE (68180-441-02) $0.0508 / mL $10.15 2017-09-06 Active

You're viewing the largest of 2 pack sizes for this product.

This pack has the lowest per-mL cost of the 2 priced pack sizes ($0.0508 NADAC).

This pack accounts for about 49% of this product's recent Medicaid fills; most go to the 1 ml pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 68180-0441-02?
NDC 68180-0441-02 contains 200 mL — 200 ml in 1 bottle.
What is the difference between NDC 68180-0441-02 and NDC 68180-0441-01?
Both are cephalexin 250 mg/5mL For Suspension — the drug itself is identical. NDC 68180-0441-02 is the 200 mL package, while NDC 68180-0441-01 is the 100 ml package. Per-mL NADAC also differs: $0.0508 here vs $0.0750 for the 100 ml pack.
What NDC number is used to bill for this package of cephalexin 250 mg/5mL For Suspension?
Bill NDC 68180-0441-02 — the 11-digit billing format is 68180044102. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage ~2 min read ▾

1 INDICATIONS AND USAGE Cephalexin USP is a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria in adults and pediatric patients aged one year and older: Respiratory tract infection ( 1.1 ) Otitis media ( 1.2 ) Skin and skin structure infections ( 1.3 ) Bone infections ( 1.4 ) Genitourinary tract infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, cephalexin for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.

( 1.6 )

1.1Respiratory Tract Infections Cephalexin for oral suspension is indicated for the treatment of respiratory tract infections caused by susceptible isolates of Streptococcus pneumoniae and Streptococcus pyogenes in adults and pediatric patients aged one year and older.

1.2Otitis Media Cephalexin for oral suspension is indicated for the treatment of otitis media caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis in adults and pediatric patients aged one year and older.

1.3Skin and Skin Structure Infections Cephalexin for oral suspension is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes in adults and pediatric patients aged one year and older.

1.4Bone Infections Cephalexin for oral suspension is indicated for the treatment of bone infections caused by susceptible isolates of Staphylococcus aureus and Proteus mirabilis in adults and pediatric patients aged one year and older .

1.5Genitourinary Tract Infections Cephalexin for oral suspension is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae in adults and pediatric patients aged one year and older .

1.6Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin for oral suspension and other antibacterial drugs, cephalexin for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Adults and patients at least 15 years of age The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered ( 2.1 ). Pediatric patients (over 1 year of age) • Otitis media: 75 to 100 mg/kg in equally divided doses every 6 hours ( 2.2 ) • All other indications: 25 to 50 mg/kg given in equally divided doses ( 2.2 ) • In severe infections: 50 to 100 mg/kg may be administered in equally divided doses ( 2.2 ) Duration of therapy ranges from 7 to 14 days depending on the infection type and severity.

( 2 ) See full prescribing information directions for mixing cephalexin for oral suspension ( 2.3 ) Dosage adjustment is required in patients with severe and end stage renal disease (ESRD) defined as creatinine clearance below 30 mL/min. ( 2.4 )

2.1Recommended Dosage for Adults and Pediatric Patients at Least 15 Years of Age The recommended dosage of oral cephalexin is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 to 14 days. For more severe infections larger doses of oral cephalexin may be needed, up to 4 grams daily in two to four equally divided doses.

2.2Recommended Dosage for Pediatric Patients (over 1 year of age) The recommended total daily dose of oral cephalexin for pediatric patients is 25 to 50 mg/kg given in equally divided doses for 7 to 14 days. In the treatment of β-hemolytic streptococcal infections, duration of at least 10 days is recommended. In severe infections, a total daily dose of 50 to 100 mg/kg may be administered in equally divided doses.

For the treatment of otitis media, the recommended daily dose is 75 to 100 mg/kg given in equally divided doses. See Table 1 for the dosage of Cephalexin for oral suspension by weight for pediatric patients. Table 1: Dosage by Weight of Cephalexin for Oral Suspension for Pediatric Patients *teaspoon =tsp Weight of Pediatric Patient Cephalexin for Oral Suspension (125 mg/5mL) Cephalexin for Oral Suspension (250 mg/5mL) OPTION 1 Dosage Dosage 10 kg ½ to 1 tsp * four times a day ¼ to ½ tsp four times a day 20 kg 1 to 2 tsp four times a day ½ to 1 tsp four times a day 40 kg 2 to 4 tsp four times a day 1 to 2 tsp four times a day OPTION 2 10 kg 1 to 2 tsp two times a day ½ to 1 tsp two times a day 20 kg 2 to 4 tsp two times a day 1 to 2 tsp two times a day 40 kg 2 to 4 tsp two times a day 2 to 4 tsp two times a day

2.3Direction for Mixing cephalexin for oral susapension 125 mg/5 mL (100 mL when mixed): Prepare suspension time at dispensing. Add to the bottle a total of 69 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, shaking well after each addition.

The resulting suspension will contain cephalexin monohydrate equivalent to 125 mg cephalexin in each 5 mL (teaspoonful). 125 mg/5 mL (200 mL when mixed): Prepare suspension time at dispensing. Add to the bottle a total of 138 mL of water.

For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, shaking well after each addition. The resulting suspension will contain cephalexin monohydrate equivalent to 125 mg cephalexin in each 5 mL (teaspoonful). 250 mg/5 mL (100 mL when mixed): Prepare suspension time at dispensing.

Add to the bottle a total of 69 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, shaking well after each addition. The resulting suspension will contain cephalexin monohydrate equivalent to 250 mg cephalexin in each 5 mL (teaspoonful).

250 mg/5 mL (200 mL when mixed): Prepare suspension time at dispensing. Add to the bottle a total of 138 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, shaking well after each addition.

The resulting suspension will contain cephalexin monohydrate equivalent to 250 mg cephalexin in each 5 mL (teaspoonful). After mixing, the different concentrations and volumes of the suspension as described above,…

💊 Dosage Forms and Strengths 62 words ▾

3 DOSAGE FORMS AND STRENGTHS For oral suspension 125 mg/5mL and 250 mg/5mL of cephalexin as pink coloured powder for reconstitution in a multidose bottle that forms a pink coloured suspension with characteristic odour on constitution for each strength, respectively. For oral suspension: 125 mg/5mL and 250 mg/5mL of cephalexin as a powder in a multi-dose bottle for reconstitution ( 3 )

⛔ Contraindications 41 words ▾

4 CONTRAINDICATIONS Cephalexin is contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. Patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. ( 4 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Serious hypersensitivity (anaphylactic) reactions: Prior to use, inquire regarding history of hypersensitivity to beta-lactam antibacterial drugs. Discontinue the drug if signs or symptoms of an allergic reaction occur and institute supportive measures. ( 5.1 ) Clostridioides difficile -associated diarrhea (CDAD): Evaluate if diarrhea occurs.

( 5.2 ) Direct Coomb's Test Seroconversion: If anemia develops during or after cephalexin therapy, evaluate for drug-induced hemolytic anemia. ( 5.3 ) Seizure Potential : Use lower dose in patients with renal impairment. ( 5.4 )

5.1Hypersensitivity Reactions Allergic reactions in the form of rash, urticaria, angioedema, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been reported with the use of cephalexin. Before therapy with cephalexin for oral suspension is instituted, inquire whether the patient has a history of hypersensitivity reactions to cephalexin, cephalosporins, penicillins, or other drugs. Cross-hypersensitivity among beta-lactam antibacterial drugs may occur in up to 10% of patients with a history of penicillin allergy.

If an allergic reaction to cephalexin for oral suspension occurs, discontinue the drug and institute appropriate treatment.

5.2Clostridioides difficile -Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cephalexin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B, which contribute to the development of CDAD.

Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.

5.3Direct Coombs’ Test Seroconversion Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibacterial drugs including cephalexin. Acute intravascular hemolysis induced by cephalexin therapy has been reported. If anemia develops during or after cephalexin therapy, perform a diagnostic work-up for drug-induced hemolytic anemia, discontinue cephalexin and institute appropriate therapy.

5.4Seizure Potential Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures occur, discontinue cephalexin for oral suspension. Anticonvulsant therapy can be given if clinically indicated.

5.5Prolonged Prothrombin Time Cephalosporins may be associated with prolonged prothrombin time. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antibacterial therapy, and patients receiving anticoagulant therapy. Monitor prothrombin time in patients at risk and manage as indicated.

5.6Development of Drug-Resistant Bacteria Prescribing cephalexin for oral suspension in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Prolonged use of cephalexin for oral suspension may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs dur…

🤒 Adverse Reactions ~2 min read ▾

6 ADVERSE REACTIONS The following serious events are described in greater detail in the Warning and Precautions section: Hypersensitivity reactions [ see Warning and Precautions ( 5.1 ) ] Clostridioides difficile -associated diarrhea [ see Warnings and Precautions ( 5.2 ) ] Direct Coombs' Test Seroconversion [ see Warnings and Precautions ( 5.3 ) ] Seizure Potential [ see Warnings and Precautions ( 5.4 ) ] Prolonged Prothrombin Time [ see Warnings and Precautions ( 5.5 )] Development of Drug-Resistant Bacteria [ see Warnings and Precautions ( 5.6 )] The most common adverse reactions associated with cephalexin for oral suspension include diarrhea, nausea, vomiting, dyspepsia and abdominal pain.

( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, the most frequent adverse reaction was diarrhea. Nausea and vomiting, dyspepsia, gastritis, and abdominal pain have also occurred.

As with penicillins and other cephalosporins, transient hepatitis and cholestatic jaundice have been reported. Other reactions have included hypersensitivity reactions, genital and anal pruritus, genital candidiasis, vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations, arthralgia, arthritis, and joint disorder. Reversible interstitial nephritis has been reported.

Eosinophilia, neutropenia, thrombocytopenia, hemolytic anemia, and slight elevations in aspartate transaminase (AST) and alanine transaminase (ALT) have been reported. In addition to the adverse reactions listed above that have been observed in patients treated with cephalexin, the following adverse reactions and other altered laboratory tests have been reported for cephalosporin class antibacterial drugs: Other Adverse Reactions : Fever, colitis, aplastic anemia, hemorrhage, renal dysfunction, and toxic nephropathy.

Altered Laboratory Tests : Prolonged prothrombin time, increased blood urea nitrogen (BUN), increased creatinine, elevated alkaline phosphatase, elevated bilirubin, elevated lactate dehydrogenase (LDH), pancytopenia, leukopenia, and agranulocytosis.

🔄 Drug Interactions 150 words ▾

7 DRUG INTERACTIONS Metformin: increased metformin concentrations. Monitor for hypoglycemia. ( 7.1 ) Probenecid-The renal excretion of cephalexin for oral suspension is inhibited by probenecid. Co-administration of probenecid with cephalexin for oral suspension is not recommended. ( 7.2 ) Administration of cephalexin for oral suspension may result in a false-positive reaction for glucose in the urine. ( 7.3 )

7.1Metformin Administration of cephalexin with metformin results in increased plasma metformin concentrations and decreased renal clearance of metformin. Careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin [ see Clinical Pharmacology ( 12.3 ) ].

7.2Probenecid The renal excretion of cephalexin is inhibited by probenecid. Co-administration of probenecid with cephalexin is not recommended.

7.3Interaction with Laboratory or Diagnostic Testing A false-positive reaction may occur when testing for the presence of glucose in the urine using Benedict's solution or Fehling's solution.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Renal Impairment: Monitor patients longer for toxicity and drug interactions due to delayed clearance. ( 8.6 )

8.1Pregnancy Risk Summary Available data from published epidemiologic studies and pharmacovigilance case reports over several decades of cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (MRHD) based on body surface area during organogenesis revealed no evidence of harm to the fetus (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Animal Data In animal reproduction studies, pregnant mice and rats administered oral cephalexin doses of 250 or 500 mg/kg/day (approximately 0.6 and 1.2 times the MRHD) based on body surface area, respectively during the period of organogenesis showed no adverse effects on embryofetal development. In a pre- and post-natal developmental toxicity study, pregnant rats that received oral doses of 250 or 500 mg/kg/day of cephalexin from Day 15 of pregnancy to litter Day 21 showed no adverse effects on parturition, litter size, or growth of offspring.

8.2Lactation Risk Summary Data from a published clinical lactation study report that cephalexin is present in human milk. The relative infant dose (RID) is considered to be <l% of the maternal weight adjusted dose. There are limited data on the effects of cephalexin on the breastfed child.

There are no data on the effects of cephalexin on milk production. The developmental health benefits of breastfeeding should be considered along with the mother's clinical need for cephalexin and any potential adverse effects on the breastfed child from cephalexin or from the underlying maternal condition.

8.4Pediatric Use The safety and effectiveness of cephalexin have been established in pediatric patients aged one year and older in clinical trials [see Indications and Usage ( 1.1 – 1.5 )] for the dosages described in the dosage and administration section [see Dosage and Administration ( 2.1 , 2.2) ]. The safety and effectiveness of cephalexin have not been established in pediatric patients younger than one year old.

8.5Geriatric Use Of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. This drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [ see Warnings and Precautions ( 5.4 ) ].

8.6Renal Impairment Cephalexin should be administered with careful monitoring in the presence of renal impairment (creatinine clearance < 30 mL/min, with or without dialysis). Under such conditions, careful clinical observation and laboratory studies renal function monitoring should be conducted because safe dosage may be lower than that usually recommended [ see Dosage and Administration ( 2.3 ) ]. Monitor patients longer for toxicity and drug interactions due to delayed clearance.

🤰 Pregnancy ~1 min read ▾

8.1Pregnancy Risk Summary Available data from published epidemiologic studies and pharmacovigilance case reports over several decades of cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (MRHD) based on body surface area during organogenesis revealed no evidence of harm to the fetus (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Animal Data In animal reproduction studies, pregnant mice and rats administered oral cephalexin doses of 250 or 500 mg/kg/day (approximately 0.6 and 1.2 times the MRHD) based on body surface area, respectively during the period of organogenesis showed no adverse effects on embryofetal development. In a pre- and post-natal developmental toxicity study, pregnant rats that received oral doses of 250 or 500 mg/kg/day of cephalexin from Day 15 of pregnancy to litter Day 21 showed no adverse effects on parturition, litter size, or growth of offspring.

🧒 Pediatric Use 69 words ▾

8.4Pediatric Use The safety and effectiveness of cephalexin have been established in pediatric patients aged one year and older in clinical trials [see Indications and Usage ( 1.1 – 1.5 )] for the dosages described in the dosage and administration section [see Dosage and Administration ( 2.1 , 2.2) ]. The safety and effectiveness of cephalexin have not been established in pediatric patients younger than one year old.

🧓 Geriatric Use 105 words ▾

8.5Geriatric Use Of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. This drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [ see Warnings and Precautions ( 5.4 ) ].

🆘 Overdosage 44 words ▾

10 OVERDOSAGE Symptoms of oral overdose may include nausea, vomiting, epigastric distress, diarrhea, and hematuria. In the event of an overdose, institute general supportive measures. Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cephalexin.

🧬 Clinical Pharmacology ~2 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Cephalexin is a cephalosporin antibacterial drug [ see Microbiology ( 12.4 ) ].

12.3Pharmacokinetics Absorption: Cephalexin is acid stable and may be given without regard to meals. Following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 mcg/mL, respectively, were obtained at 1 hour. Serum levels were detectable 6 hours after administration (at a level of detection of 0.2 mcg/mL).

Distribution: Cephalexin is approximately 10% to 15% bound to plasma proteins. Excretion: Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours.

During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 mcg/mL respectively. Drug Interactions: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean C max and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.

12.4Microbiology Mechanism of Action Cephalexin is a bactericidal agent that acts by the inhibition of bacterial cell-wall synthesis. Resistance Methicillin-resistant staphylococci and most isolates of enterococci are resistant to cephalexin. Cephalexin is not active against most isolates of Enterobacter spp., Morganella morganii, and Proteus vulgaris .

Cephalexin has no activity against Pseudomonas spp. , or Acinetobacter calcoaceticus. Penicillin-resistant Streptococcus pneumoniae is usually cross-resistant to beta-lactam antibacterial drugs. Antimicrobial Activity Cephalexin has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections [ see Indications and Usage ( 1 ) ].

Gram-positive bacteria Staphylococcus aureus (methicillin-susceptible isolates only) Streptococcus pneumoniae (penicillin-susceptible isolates) Streptococcus pyogenes Gram-negative bacteria Escherichia coli Haemophilus influenzae Klebsiella pneumoniae Moraxella catarrhalis Proteus mirabilis Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

🧬 Mechanism of Action 17 words ▾

12.1Mechanism of Action Cephalexin is a cephalosporin antibacterial drug [ see Microbiology ( 12.4 ) ].

📦 How Supplied / Storage and Handling 140 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Cephalexin for Oral Suspension USP is a Pink coloured powder forming pink coloured suspension with characteristic odour on constitution for the 125mg/5mL and 250mg/5mL strength, respectively, supplied as follows: The 125 mg per 5 mL for oral suspension is available as follows: 100-mL Bottles NDC 68180-440-01 200-mL Bottles NDC 68180-440-02 The 250 mg per 5 mL for oral suspension is available as follows: 100-mL Bottles NDC 68180-441-01 200-mL Bottles NDC 68180-441-02 Directions for mixing are included elsewhere in the labeling [see Dosage and Administration ( 2.3 )] .

Prior to mixing, store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Shake well before using. Keep tightly closed.

After mixing, store in refrigerator. May be kept for 14 days without significant loss of potency [see Dosage and Administration ( 2.3 )] .

📋 Description 137 words ▾

11 DESCRIPTION Cephalexin for oral suspension, USP is a semisynthetic cephalosporin antibacterial drug intended for oral administration. It is 7- (D-α-Amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate. Cephalexin has the molecular formula C 16 H 17 N 3 O 4 S • H 2 O and the molecular weight is 365.41.

Cephalexin has the following structural formula: Cephalexin for oral suspension, USP is supplied in a multi-dose bottle as pink coloured powder containing 125 mg/5 mL or 250 mg/5 mL of cephalexin for oral use following reconstitution with water. Freshly reconstituted solutions of cephalexin yield a pink coloured suspension with characteristic odour on constitution for the 125 mg/5 mL and 250 mg/5 mL strengths, respectively. The inactive ingredients in the cephalexin for oral suspension are colloidal silicon dioxide, FD&C Red No.

40, sodium benzoate, strawberry flavor, sucrose, xanthan gum. Image 01

💬 Information for Patients ~1 min read ▾

17 PATIENT COUNSELING INFORMATION Allergic Reactions Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. Ask the patient about any previous hypersensitivity reactions to cephalexin, other beta-lactams (including cephalosporins) or other allergens ( 5.1 ) Diarrhea Advise patients that diarrhea is a common problem caused by antibacterial drugs and usually resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection.

If severe watery or bloody diarrhea develops, advise patients to contact their healthcare provider. Antibacterial Resistance Patients should be counseled that antibacterial drugs including cephalexin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold).

When cephalexin is prescribed to treat a bacterial infection, tell patients that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cephalexin or other antibacterial drugs in the future. Manufactured for: Lupin Pharmaceuticals, Inc.

Naples, FL 34108 United States Manufactured by: Lupin Limited Mandideep 462046 India Revised: May 2026 ID: 284100 Image 02

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 68180-0440-01 · Lupin 68180-0445-01 · Lupin →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.